Skip to content

Study of amide proton transfer weighted MRI in predicting the efficacy of neoadjuvant therapy for advanced rectal cancer

Study of amide proton transfer weighted MRI in predicting the efficacy of neoadjuvant therapy for advanced rectal cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100048834
Enrollment
Unknown
Registered
2021-07-18
Start date
2022-09-01
Completion date
Unknown
Last updated
2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced rectal cancer

Interventions

pCR group:surgical resection after neoadjuvant treatment
Non-pCR group:surgical resection after neoadjuvant treatment

Sponsors

Yunnan Cancer Hospital (The Third Affiliated Hospital of Kunming Medical University)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patients with rectal cancer confirmed by colonoscopy and biopsy; 2. Clinical stage is T3, T4 locally advanced patients, and the lesion range is >=1.0cm; 3. Inflexible Proctoscopy examines the lower edge of the tumor within 10 cm from the anal edge; 4. Untreated patients at first diagnosis; 5. Patients without contraindications to magnetic resonance examination; 6. surgery after neoadjuvant treatment, and After the operation, complete materials were collected and TRG graded.

Exclusion criteria

Exclusion criteria: 1. Patients who abandon treatment or change therapy during the treatment; 2. Patients with multiple cancers; 3. Patients with poor multimodal MR imaging image quality.

Design outcomes

Primary

MeasureTime frame
The ADC signal;

Secondary

MeasureTime frame
APTw;DKI parameters;IVIM parameters;Multimodal MRI;MSI Type;Tumor budding grade;KRAS, NRAS, BRAF gene mutations and mutation type;Carcinoembryonic antigen;Carbohydrate antigen 19-919-9;TRG classification;

Countries

China

Contacts

Public ContactLi Zhenhui

Yunnan Cancer Hospital (The Third Affiliated Hospital of Kunming Medical University)

Lizhenhui621@qq.com+86 13698136132

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026